Retatrutide, a new dual agonist of the GLP-1 target and glucose-dependent insulinotropic polypeptide (GIP) target, is demonstrating promising outcomes in preliminary patient trials . Recent research https://shopretatrutidepeptide.com/retatrutide-research-knowledge-hub/